CAS NO: | 434-13-9 |
规格: | ≥98% |
包装 | 价格(元) |
1g | 电议 |
2g | 电议 |
5g | 电议 |
10g | 电议 |
50g | 电议 |
Molecular Weight (MW) | 376.57 |
---|---|
Formula | C24H40O3 |
CAS No. | 434-13-9 |
Storage | -20℃ for 3 years in powder form |
-80℃ for 2 years in solvent | |
Solubility (In vitro) | DMSO: 75 mg/mL (199.2 mM) |
Water: <1 mg/mL | |
Ethanol: 47 mg/mL (124.8 mM) | |
Other info | Chemical Name: 3alpha-Hydroxy-5beta-cholan-24-oic acid InChi Key: SMEROWZSTRWXGI-HVATVPOCSA-N InChi Code: InChI=1S/C24H40O3/c1-15(4-9-22(26)27)19-7-8-20-18-6-5-16-14-17(25)10-12-23(16,2)21(18)11-13-24(19,20)3/h15-21,25H,4-14H2,1-3H3,(H,26,27)/t15-,16-,17-,18+,19-,20+,21+,23+,24-/m1/s1 SMILES Code: C[C@H](CCC(O)=O)[C@H]1CC[C@@]2([H])[C@]3([H])CC[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C |
Synonyms | Lithocolic acid; Lithocholate; 3α-Hydroxy-5β-cholanic acid |
In Vitro | In vitro activity: Lithocholic acid (LCA) is a hydrophobic secondary bile acid that is primarily formed in the intestine by the bacterial 7α-dehydroxylation of chenodeoxycholic acid. LCA causes intrahepatic cholestasis (cessation or impairment of bile flow). LCA activates PXR (pregnane X receptor), and the LCA-induced severe liver damage can be protected by the activation of PXR. LCA is a ligand for farnesoid X receptor (FXR) with EC50 of 3.8 μM. LCA directly binds VDR (vitamin D receptor) with Ki of 29μM, activates VDR (vitamin D receptor) 30 μM, with much more sensitivity than the other nuclear receptors (eg. PXR, FXR), and its toxic effect is thus protected. LCA has tumor-promoting activity, inhibits mammalian DNA Polymerase β with IC50 of 15 μM Kinase Assay: Ligand binding is performed using lysates from COS-7 cells transfected with expression plasmids for VDR or RXRα. Binding is performed overnight at 4°C in lysate buffer with 0.71 nM (18 Ci/mmol) [3H]1,25(OH)2D3 and bile acid competitor. Unbound [3H]1,25(OH)2D3 is removed by adsorption to dextran-coated charcoal and the supernatant removed for scintillation counting. Ki values are calculated from a computer fit of competition curves from triplicate assays. |
---|---|
In Vivo | Administration of LCA and its conjugates to rodents causes intrahepatic cholestasis,a pathogenic state characterized by decreased bile flow and the accumulation of bile constituents in the liver and blood. In DMH (dimethyldydrazine)-induced murine carcinogenesis model, LCA suppresses apoptosis almost completely in premalignant colon. LCA activates VDR, induces expression in vivo of CYP3A, a cytochrome P450 enzyme that detoxifies LCA in the liver and intestine. |
Animal model | Mice |
Formulation & Dosage | Dissolved in Corn oil; 125 mg/kg; i.p. injection |
References | Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3369-74; Science. 2002 May 17;296(5571):1313-6. |